Kenvue Inc. Common Stock vs Solstice Advanced Materials Inc. Common Stock — how do they compare? Kenvue Inc. Common Stock trades at $18.12 (market cap $34.11B), while Solstice Advanced Materials Inc. Common Stock trades at $59.92 (market cap $9.68B). The key difference: Kenvue Inc. Common Stock is far larger — about 3.5× Solstice Advanced Materials Inc. Common Stock's market cap, and Kenvue Inc. Common Stock pays the higher dividend (4.73%). Which is the better fit depends on your goals — on Pluang, investors hold Kenvue Inc. Common Stock for 1 Days and Solstice Advanced Materials Inc. Common Stock for 0 Days on average.
| KVUE | SOLS | |
|---|---|---|
Market Cap | $34.11B | $9.68B |
Volume | 27,388,811 | 1,519,067 |
Sector | Consumer Staples | Basic Materials |
52-Week High | $19.83 | $88.60 |
52-Week Low | $14.11 | $41.43 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $41.62B | $11.35B |
Dividend Yield | 4.73% | 0.49% |
Signals from Pluang's Aura AI — not financial advice
Kenvue (KVUE) trades at $17.76, down 0.39% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $15.12B in 2025, with a net income margin of 10.76% and a P/E ratio of 20.89. Recent news highlights conditional EU approval for Kimberly-Clark's $40B acquisition of Kenvue, potentially impacting future operations and shareholder returns.
The outlook is mixed, with strong profitability and consistent dividend payments offering stability, but the pending acquisition introduces uncertainty. Risks include integration challenges and market volatility. Analyst consensus is a Hold with a $19.50 price target, suggesting limited near-term upside from current levels.
Solstice Advanced Materials (SOLS) trades at $60.91, up 0.33% with neutral technical signals. The company shows strong profitability with 30.64% gross margins and 14.95% ROE, though Q4 2025 earnings missed expectations. Recent developments include a $49M R&D expansion and termination of the Element Solutions merger, with the board authorizing a $500M share repurchase program. Analyst consensus is bullish with 80% buy ratings and a $80.22 price target representing 32% upside potential.
SOLS presents a compelling growth story with consistent earnings beats and institutional accumulation, though elevated P/E of 46.07 warrants caution. Key risks include execution challenges post-merger termination and margin pressure as profit margins declined from 6.09% to 5.12% year-over-year. The stock offers substantial upside if management delivers on growth initiatives while maintaining current profitability levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →Solstice Advanced Materials Inc. is a specialty materials company spun off from Honeywell in 2025, producing low-global-warming-potential refrigerants, blowing agents, and industrial solvents through its Refrigerants and Applied Solutions segment. Its Electronic and Specialty Materials segment supplies semiconductor materials, high-strength fibers, and healthcare-packaging films.
Read more on SOLS →